DexCom trust plans sale of 2,000 common shares

DexCom, Inc. (DXCM) has a planned sale by The Foletta Family Trust under a Form 144 notice.

Rhea-AI Filing Summary

DexCom, Inc. (DXCM) has a planned sale by The Foletta Family Trust under a Form 144 notice. The trust intends to sell 2,000 shares of common stock through UBS Financial Services on NASDAQ, with an indicated aggregate value of $170,640.00. The shares derive from 2,000 vested RSUs granted by the issuer on 05/31/2019.

The filing also lists recent sales by the trust: 4,000 shares of common stock sold on 06/15/2026 for $296,539.60, and 2,000 shares sold on 07/31/2026 for $160,000.00. These transactions provide context for the trust’s ongoing disposition of DXCM shares.

Key Figures

Planned shares to be sold: 2,000 shares Aggregate value of planned sale: $170,640.00 RSUs vested: 2,000 +4 more

7 metrics

Planned shares to be sold 2,000 shares Common stock indicated for sale through UBS Financial Services on NASDAQ

Aggregate value of planned sale $170,640.00 Total value for 2,000 common shares in planned disposition

RSUs vested 2,000 Vested RSUs from issuer dated 05/31/2019

Shares sold on 06/15/2026 4,000 shares Common stock sold by The Foletta Family Trust for $296,539.60

Proceeds on 06/15/2026 sale $296,539.60 Aggregate consideration for 4,000 common shares

Shares sold on 07/31/2026 2,000 shares Common stock sold by The Foletta Family Trust for $160,000.00

Proceeds on 07/31/2026 sale $160,000.00 Aggregate consideration for 2,000 common shares

Key Terms

Form 144, Vested RSUs, Securities Sold During The Past 3 Months, The Foletta Family Trust

4 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Vested RSUs financial

"Common | 05/31/2019 | Vested RSUs | Issuer"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

The Foletta Family Trust financial

"The Foletta Family Trust dtd 1/30/2015 6340 SEQUENCE DRIVE"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does DexCom (DXCM) report in this Form 144 notice?

DexCom reports that The Foletta Family Trust has filed a Form 144 indicating an intent to sell 2,000 shares of DXCM common stock, with an aggregate value of $170,640.00, through UBS Financial Services on NASDAQ.

How many DexCom (DXCM) shares are planned for sale under this Form 144?

The Foletta Family Trust plans to sell 2,000 shares of DexCom common stock. The filing lists an aggregate value of $170,640.00 for this planned transaction, with UBS Financial Services as broker and NASDAQ as the trading market.

What prior DexCom (DXCM) share sales does the Form 144 disclose?

The filing discloses that The Foletta Family Trust sold 4,000 shares of DXCM on 06/15/2026 for $296,539.60 and 2,000 shares on 07/31/2026 for $160,000.00. These sales occurred within the three months preceding the planned sale.

What is the source of the DexCom (DXCM) shares being sold?

The shares relate to vested RSUs from DexCom. The Form 144 notes 2,000 vested RSUs that vested on 05/31/2019, issued by DexCom, as the underlying securities for the trust’s planned disposition.

Who is the selling security holder in this DexCom (DXCM) Form 144?

The selling security holder is The Foletta Family Trust dtd 1/30/2015, with an address at 6340 Sequence Drive, San Diego, CA 92121. The trust is listed as the owner of the DXCM common stock being sold.

Which broker and market are involved in the DexCom (DXCM) planned sale?

The planned sale of DexCom shares is associated with UBS Financial Services, Inc. as broker, located at 11 Madison Ave, New York, NY 10010. The common stock is indicated to trade on NASDAQ in this Form 144 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 04:10 PM Accepted by SEC EDGAR 08/03/2026 - 04:10 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001236389
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DEXCOM INC
SEC File Number	000-51222
Address of Issuer	6340 SEQUENCE DRIVE SAN DIEGO CALIFORNIA 92121
Phone	8582000200
Name of Person for Whose Account the Securities are To Be Sold	FOLETTA MARK G
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	2000	170640.00	377360765	08/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/31/2019	Vested RSUs	Issuer			2000	05/31/2019	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
The Foletta Family Trust dtd 1/30/2015 6340 SEQUENCE DRIVE SAN DIEGO CA 92121	Common	06/15/2026	4000	296539.60
The Foletta Family Trust dtd 1/30/2015 6340 SEQUENCE DRIVE SAN DIEGO CA 92121	Common	07/31/2026	2000	160000.00

144: Remarks and Signature

Remarks	The shares covered under this filing are being sold under the Foletta Family Trust dtd 1/30/2015.
Date of Notice	08/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Mark Foletta
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)